In a real-life setting, golimumab showed effectiveness to treat psoriatic arthritis, including  cutaneous and musculoskeletal manifestations. Golimumab's efficacy and drug survival were not impacted by comorbidities and patient-associated characteristics, as per the findings of a study published in Clinical Rheumatology. Investigators aimed to examine golimumab's efficacy to improve joint, periarticular structures and cutaneous manifestations in psoriatic arthritis.

This retrospective observational study recruited psoriatic arthritis people treated with golimumab. At baseline (T0) and after six, twelve, 24, 36, and 48 months of golimumab therapy, collection of clinical and lab records was done. With the aid of paired t-test or Wilcoxon test, comparisons were carried out. With the aid of Kaplan-Meier estimates, an analysis of drug survival rates was done.

The collection of data was done from 105 participants. Psoriasis occurred in 80% of people, erosions in 36.2%, enthesitis in 78%, peripheral arthritis in 63.8% and axial arthritis in 35.3%. Metabolic syndrome (19%) and cardiovascular diseases (31.4%) were the major comorbidities. Substantial improvements in cutaneous and articular psoriasis were reported at 48 months of golimumab treatment in clinical (Disease Activity in Psoriatic Arthritis [DAPSA], Psoriasis Area Severity Index [PASI], Bath Ankylosing Spondylitis disease activity index [BASDAI]) and lab (C-reactive protein) indexes.

Gender, body mass index, smoking habit, and line of therapy did not influence therapy efficacy nor persistence. After 48 months, 42% of participants discontinued golimumab. Inadequate response or loss of efficacy (28.6%) was the most common reason. Thus, a 48-month golimumab high drug persistence of psoriatic arthritis people was reported in real-life, in people presenting higher disease activity, greater prevalence of comorbidities, and more than 1 line of therapy at the baseline.